Novartis Pharma (encorafenib (LGX818))
M&A
STATUS
Asset Purch.
LATEST DEAL TYPE
1
FINANCING ROUNDS
Description
A key protein kinase in the RAS/RAF/MEK/ERK signaling pathway. It regulates several key cellular activities including proliferation, differentiation, migration, survival and angiogenesis.
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Business Products and Services
Acquirer
Primary Office
- Boulder, CO
- United States
Novartis Pharma (encorafenib (LGX818)) Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Novartis Pharma (encorafenib (LGX818))‘s full profile, request access.
Request full access to PitchBookNovartis Pharma (encorafenib (LGX818)) Former Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Novartis Pharma (encorafenib (LGX818))‘s full profile, request access.
Request full access to PitchBook